Toll Free: 1-888-928-9744
Published: Nov, 2014 | Pages:
110 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Thyroid Cancer - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Thyroid Cancer - Pipeline Review, H2 2014', provides an overview of the Thyroid Cancer's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Thyroid Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Thyroid Cancer and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Thyroid Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Thyroid Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Thyroid Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Thyroid Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Thyroid Cancer - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Thyroid Cancer pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Thyroid Cancer Overview 8 Therapeutics Development 9 Pipeline Products for Thyroid Cancer - Overview 9 Pipeline Products for Thyroid Cancer - Comparative Analysis 10 Thyroid Cancer - Therapeutics under Development by Companies 11 Thyroid Cancer - Therapeutics under Investigation by Universities/Institutes 13 Thyroid Cancer - Pipeline Products Glance 14 Late Stage Products 14 Clinical Stage Products 15 Early Stage Products 16 Thyroid Cancer - Products under Development by Companies 17 Thyroid Cancer - Products under Investigation by Universities/Institutes 18 Thyroid Cancer - Companies Involved in Therapeutics Development 19 AstraZeneca PLC 19 Azaya Therapeutics Incorporated 20 Bio-Path Holdings, Inc. 21 Biovista Inc. 22 centrose llc 23 Ecrins Therapeutics SAS 24 Eisai Co., Ltd. 25 GlaxoSmithKline plc 26 Novartis AG 27 Translational Therapeutics, Inc. 28 Trophogen, Inc. 29 Vascular Biogenics Ltd. 30 Thyroid Cancer - Therapeutics Assessment 31 Assessment by Monotherapy Products 31 Assessment by Target 32 Assessment by Mechanism of Action 35 Assessment by Route of Administration 37 Assessment by Molecule Type 39 Drug Profiles 41 BP-100-1.02 - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 BVA-501 - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 BVA-701 - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 docetaxel liposomal - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 EDC-1 - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 ETD-5 - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 everolimus - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 Gene Therapy to Activate p53 for Oncology - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 GSK-2256098 - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 lenvatinib - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 MVX-ONCO-1 - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 panobinostat - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 pazopanib hydrochloride - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 Recombinant Protein to Agonize VEGF for Thyroid and Multiple Other Cancers - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 selumetinib sulfate - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 Small Molecules to Antagonize ALK for Oncology - Drug Profile 76 Product Description 76 Mechanism of Action 76 R&D Progress 76 Small Molecules to Inhibit PAK for Thyroid Cancer - Drug Profile 77 Product Description 77 Mechanism of Action 77 R&D Progress 77 TR-1401 - Drug Profile 78 Product Description 78 Mechanism of Action 78 R&D Progress 78 TRX-201 - Drug Profile 79 Product Description 79 Mechanism of Action 79 R&D Progress 79 VB-111 - Drug Profile 80 Product Description 80 Mechanism of Action 80 R&D Progress 80 Thyroid Cancer - Recent Pipeline Updates 81 Thyroid Cancer - Dormant Projects 98 Thyroid Cancer - Discontinued Products 99 Thyroid Cancer - Product Development Milestones 100 Featured News & Press Releases 100 Nov 26, 2014: Eisai Opens Multi-million Pound High Tech Global Potent Packaging Facility For New Cancer Treatment in Hatfield, UK 100 Oct 14, 2014: U.S. FDA Grants Eisai's Investigational Agent Lenvatinib Priority Review Designation for the Treatment of Advanced Thyroid Cancer 101 Sep 17, 2014: Eisai to Present Clinical Data on Lenvatinib at 39th ESMO Congress 102 Sep 06, 2014: Significant Improvement in Progression-Free Survival With Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer: Data Confirmed in New Subgroup Analyses 103 Aug 18, 2014: Eisai submits Marketing Approval Application for Anti cancer Agent Lenvatinib Simultaneously in Europe And U.S. 104 Jul 31, 2014: Ema Accepts Eisai's Request For Accelerated Assessment Of Anticancer Agent Lenvatinib 105 Jun 26, 2014: Eisai Submits First Marketing Authorization Application for Anticancer agent Lenvatinib in Japan 105 May 31, 2014: Lenvatinib Phase III Results Show Significant Improvement In Progression-Free Survival In Patients With Radioiodine-Refractory Differentiated Thyroid Cancer 106 May 15, 2014: Eisai to Present Abstracts On Lenvatinib At 50th ASCO Annual Meeting 107 Feb 03, 2014: Phase III Trial Shows Lenvatinib Meets Primary Endpoint Of Progression Free Survival Benefit in Treatment Of Radioiodine-refractory Differentiated Thyroid Cancer 108 Appendix 109 Methodology 109 Coverage 109 Secondary Research 109 Primary Research 109 Expert Panel Validation 109 Contact Us 110 Disclaimer 110
List of Tables Number of Products under Development for Thyroid Cancer, H2 2014 9 Number of Products under Development for Thyroid Cancer - Comparative Analysis, H2 2014 10 Number of Products under Development by Companies, H2 2014 12 Number of Products under Investigation by Universities/Institutes, H2 2014 13 Comparative Analysis by Late Stage Development, H2 2014 14 Comparative Analysis by Clinical Stage Development, H2 2014 15 Comparative Analysis by Early Stage Development, H2 2014 16 Products under Development by Companies, H2 2014 17 Products under Investigation by Universities/Institutes, H2 2014 18 Thyroid Cancer - Pipeline by AstraZeneca PLC, H2 2014 19 Thyroid Cancer - Pipeline by Azaya Therapeutics Incorporated, H2 2014 20 Thyroid Cancer - Pipeline by Bio-Path Holdings, Inc., H2 2014 21 Thyroid Cancer - Pipeline by Biovista Inc., H2 2014 22 Thyroid Cancer - Pipeline by centrose llc, H2 2014 23 Thyroid Cancer - Pipeline by Ecrins Therapeutics SAS, H2 2014 24 Thyroid Cancer - Pipeline by Eisai Co., Ltd., H2 2014 25 Thyroid Cancer - Pipeline by GlaxoSmithKline plc, H2 2014 26 Thyroid Cancer - Pipeline by Novartis AG, H2 2014 27 Thyroid Cancer - Pipeline by Translational Therapeutics, Inc., H2 2014 28 Thyroid Cancer - Pipeline by Trophogen, Inc., H2 2014 29 Thyroid Cancer - Pipeline by Vascular Biogenics Ltd., H2 2014 30 Assessment by Monotherapy Products, H2 2014 31 Number of Products by Stage and Target, H2 2014 33 Number of Products by Stage and Mechanism of Action, H2 2014 36 Number of Products by Stage and Route of Administration, H2 2014 38 Number of Products by Stage and Molecule Type, H2 2014 40 Thyroid Cancer Therapeutics - Recent Pipeline Updates, H2 2014 81 Thyroid Cancer - Dormant Projects, H2 2014 98 Thyroid Cancer - Discontinued Products, H2 2014 99
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.